A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of KTE-X19 in Adult Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Brexucabtagene autoleucel (KTE-X19) is a CAR T-cell therapy targeting CD19, specifically developed for adult patients with relapsed/refractory chronic lymphocytic leukemia (r/r CLL) and small lymphocytic lymphoma (r/r SLL). The therapy aims to address a significant unmet need in a patient population that has limited treatment options after multiple lines of therapy, particularly those who have previously received Bruton's tyrosine kinase (BTK) inhibitors. The termination of the development program may indicate challenges in achieving desired efficacy or safety profiles, which could impact Kite's competitive positioning in the CAR T-cell therapy market. The ongoing follow-up study (NCT05041309) may yield long-term safety and efficacy data that could influence future strategic decisions or partnerships.
Indication: Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma
Modality: cell therapy
Target: CD19 (Cluster of Differentiation 19)
Sponsor: Kite, A Gilead Company
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 24, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CD19 (Cluster of Differentiation 19)
View original source fields
Condition raw: Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma
Condition normalized: Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: CD19 (Cluster of Differentiation 19)
Target normalized: CD19 (Cluster of Differentiation 19)